BioCentriq, Kytopen expand partnership on cell therapy manufacturing technology

By The Science Advisory Board staff writers

June 6, 2023 -- BioCentriq, a contract development and manufacturing organization specializing in cell therapy, and Kytopen, a Massachusetts Institute of Technology-based startup, on Tuesday announced that they are expanding their partnership.

The collaboration, which began in March 2021, started with the firms working together to test transfection for T cells using Kytopen's Flowfect platform, as well as analyze the impact of integrating this transfection technology into the manufacturing process for autologous and allogeneic cell therapies.

The expansion aims to combine BioCentriq's process development with Kytopen's Flowfect Discover platform, increasing therapeutic developers' access to a non-viral cell engineering method, according to the firms.

The Flowfect platform uses electromechanical transfection during continuous flow, which enables efficient and precise delivery of genome engineering materials to cells, the firms said. Furthermore, the Flowfect Discover automated high-throughput gene editing device enables researchers and developers to optimize the delivery of genetic material cost-effectively at a smaller scale, allowing for a smoother transition from research to production, the companies added.

Penn State-led team develops more efficient system for delivering CRISPR to stem cells
Modified mRNA (modRNA)-based CRISPR systems improve on the transfection and knockout efficiency of plasmid-based systems in human pluripotent stem cells...
Kytopen raises $30M to commercialize Flowfect Tx
Biotechnology company Kytopen has raised $30 million in funding to commercialize Flowfect Tx, a current good manufacturing process-compliant platform...
Kytopen granted SBIR for nonviral NK cell gene editing platform
Kytopen has been awarded a Small Business Innovation Research (SBIR) grant from the U.S. National Institute of Allergy and Infectious Diseases to demonstrate...
Tevogen, BioCentriq partner to manufacture COVID-19 T-cell therapy
Tevogen Bio has partnered with contract development and manufacturing organization BioCentriq to support clinical manufacturing of Tevogen's investigational...

Copyright © 2023

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter